• PDF / 169,793 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 101 Downloads / 126 Views

DOWNLOAD

REPORT

---

1

S

Diarrhoea, vomiting and febrile neutropenia: 3 case reports In a retrospective study of 252 patients treated for locally advanced oesophageal squamous cell carcinoma (ESCC) between 2000 and 2016, three patients [ages and sexes not stated] were described, who developed diarrhoea, vomiting or febrile neutropenia following chemotherapy with cisplatin and paclitaxel [routes, times to reactions onsets and outcomes not stated]. All the patients were treatment naive with pathologically confirmed primary locally advanced ESCC. All of them received minimum two cycles of unspecified neoadjuvant platinum-based chemotherapy and underwent radical resection. After esophagectomy, all the patients received postoperative chemotherapy which began within 60 days of surgery including paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 administered in a 21-days cycle. However, the patients developed chemotherapy related diarrhoea (1 patient), vomiting (1 patient) and grade 4 febrile neutropenia (1 patient). Author comment: "After matching, 5 patients (8.5%) in the perioperative chemotherapy group had grade 3 or greater toxicities (vomiting, n=1; severe diarrhea, n=1; grade 3 febrile neutropenia, n=2; grade 4 febrile neutropenia, n=1)." Yan W, et al. Survival After Induction Chemotherapy and Esophagectomy Is Not Improved by Adjuvant Chemotherapy. Annals of Thoracic Surgery 108: 1505-1513, No. 5, Nov 2019. Available from: URL: http://doi.org/10.1016/ 803436212 j.athoracsur.2019.04.106 - China

0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 30 Nov 2019 No. 1781